Major Depressive Disorder Clinical Trials in Austin, Texas

9 studies are recruiting for major depressive disorder in Austin, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of ALTO-300 in MDD

   The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.

   Stage

   Phase 2

   Ages

   18 to 70

   Site

   Site 316, Austin, Texas

   Locations

   75 in total

   Run by

   Alto Neuroscience

   See if you can join NCT05922878 on ClinicalTrials.gov

2. A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

   A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend

   Stage

   Phase 3

   Ages

   18 to 74

   Site

   Austin Clinical Trial Partners, Austin, Texas

   Locations

   30 in total

   Run by

   Definium Therapeutics US, Inc.

   See if you can join NCT07592689 on ClinicalTrials.gov

3. A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

   The primary objective of this study is to evaluate the efficacy of osavampator (previously NBI-1065845) compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in participants with MDD.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, Austin, Texas

   Locations

   61 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT07196501 on ClinicalTrials.gov

4. A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

   This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, Austin, Texas

   Locations

   19 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT07105111 on ClinicalTrials.gov

5. Accelerated Intermittent Theta Burst in Treatment-Naive Adolescents

   This is a single-site open-label clinical trial of fMRI-guided accelerated intermittent theta burst stimulation. The goal of this clinical trial is to learn if a new form of transcranial magnetic stimulation (TMS)-known generally as accelerated intermittent theta burst stimulation (aiTBS)-is effect…

   Stage

   Not phased

   Ages

   13 to 20

   Site

   Dell Medical School at University of Texas at Austin, Austin, Texas

   Run by

   University of Texas at Austin

   See if you can join NCT06523439 on ClinicalTrials.gov

6. Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

   The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel. The main questions it aims to answer are: Does zelquistinel reduce depression scores in participants compared to participants who take a placebo (a l…

   Stage

   Phase 2

   Ages

   18 to 64

   Site

   Austin Clinical Trial Partners, Austin, Texas

   Locations

   34 in total

   Run by

   Syndeio Biosciences, Inc

   See if you can join NCT06547489 on ClinicalTrials.gov

7. A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

   Major depressive disorder (MDD; depression) is a mood disorder that causes a continued feeling of sadness and loss of interest. It is a common and serious illness that can cause both emotional and physical symptoms such as feelings of sadness, irritability, not being able to focus on activities, ti…

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Austin Clinical Trial Partners /ID# 279321, Austin, Texas

   Locations

   33 in total

   Run by

   AbbVie

   See if you can join NCT07276997 on ClinicalTrials.gov

8. Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression

   The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug sertraline (tradename Zoloft), a common selective serotonin reuptake inhibitor (SSRI) antidepressant. Our central hypothesis i…

   Stage

   Phase 4

   Ages

   18 to 65

   Site

   Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600, Austin, Texas

   Run by

   University of Texas at Austin

   See if you can join NCT05892744 on ClinicalTrials.gov

9. Psilocybin rTMS for Treatment Resistant Depression

   The purpose of this study is to determine the safety and feasibility of sequencing psilocybin therapy with a short-duration, aiTBS protocol (Stanford Accelerated Intelligent Neuromodulation Therapy, or SAINT) in individuals with treatment-resistant major depressive disorder.

   Stage

   Phase 2

   Ages

   22 to 65

   Site

   Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600, Austin, Texas

   Run by

   University of Texas at Austin

   See if you can join NCT06132178 on ClinicalTrials.gov